USA - engelska - NLM (National Library of Medicine)

aldi inc - avobenzone 3.0%, homosalate 10.0%, octisalate 5.0%, octocrylene 2.0% - sunscreen • helps prevent sunburn • if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun •on damaged or broken skin. - rash occurs

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aldi stores - 9950 - disinfectant, hospital grade - other therapeutic

Europeiska unionen - engelska - EMA (European Medicines Agency)

samsung bioepis nl b.v. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; hidradenitis suppurativa; arthritis - immunosuppressants - rheumatoid arthritisimraldi in combination with methotrexate, is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisimraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). adalimumab has not been studied in patients aged less than 2 years.enthesitis-related arthritisimraldi is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).axial spondyloarthritisankylosing spondylitis (as)imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.axial spondyloarthritis without radiographic evidence of asimraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids).psoriatic arthritisimraldi is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.psoriasisimraldi is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.paediatric plaque psoriasisimraldi is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.hidradenitis suppurativa (hs)imraldi is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5.1 and 5.2).crohn’s diseaseimraldi is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.paediatric crohn's diseaseimraldi is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or haveulcerative colitisimraldi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.paediatric ulcerative colitisimraldi is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.uveitisimraldi is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whomcorticosteroid treatment is inappropriate.paediatric uveitisimraldi is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Israel - engelska - Ministry of Health

tec-o-pharm-libra ltd - paracetamol; tramadol hydrochloride - film coated tablets - paracetamol 325 mg; tramadol hydrochloride 37.5 mg - paracetamol - paracetamol - symptomatic treatment of moderate to severe pain.the use of zaldiar should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol.

Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - maldison(500g/l) - group 1b insecticide

Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - maldison(1150g/l)+methyl eugenol+hydroxyphenylbutanone acetate - group 1b insecticide

Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - maldison - group 1b insecticide

Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - maldison(500g/l) - group 1b insecticide

Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - maldison(500g/l) - group 1b insecticide

Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - maldison - group 1b insecticide